S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:STIM

Neuronetics Stock Forecast, Price & News

$14.05
-0.60 (-4.10 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.22
Now: $14.05
$14.79
50-Day Range
$7.84
MA: $10.04
$14.27
52-Week Range
$1.25
Now: $14.05
$15.38
Volume229,808 shs
Average Volume326,351 shs
Market Capitalization$266.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.
Neuronetics logo

MarketRank

Overall MarketRank

1.11 out of 5 stars

Medical Sector

760th out of 1,480 stocks

Surgical & Medical Instruments Industry

83rd out of 135 stocks

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
CUSIPN/A
CIKN/A
Phone(610) 640-4202
Employees122

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$62.66 million
Book Value$2.57 per share

Profitability

Net Income$-29,040,000.00

Miscellaneous

Market Cap$266.60 million
Next Earnings Date3/2/2021 (Estimated)
OptionableNot Optionable
$14.05
-0.60 (-4.10 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STIM News and Ratings via Email

Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Neuronetics (NASDAQ:STIM) Frequently Asked Questions

How has Neuronetics' stock been impacted by COVID-19?

Neuronetics' stock was trading at $2.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, STIM shares have increased by 578.7% and is now trading at $14.05.
View which stocks have been most impacted by COVID-19
.

Is Neuronetics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Neuronetics stock.
View analyst ratings for Neuronetics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Neuronetics?

Wall Street analysts have given Neuronetics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neuronetics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Neuronetics' next earnings date?

Neuronetics is scheduled to release its next quarterly earnings announcement on Tuesday, March 2nd 2021.
View our earnings forecast for Neuronetics
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Monday, November, 2nd. The company reported ($0.18) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.13. The firm earned $12.45 million during the quarter, compared to the consensus estimate of $11.17 million. Neuronetics had a negative net margin of 63.77% and a negative return on equity of 82.79%.
View Neuronetics' earnings history
.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics updated its fourth quarter 2020 After-Hours earnings guidance on Tuesday, January, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $15-15.5 million, compared to the consensus revenue estimate of $13.26 million.

What price target have analysts set for STIM?

4 analysts have issued 12-month price targets for Neuronetics' stock. Their forecasts range from $8.00 to $20.00. On average, they anticipate Neuronetics' share price to reach $14.25 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price.
View analysts' price targets for Neuronetics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Neuronetics?

Neuronetics saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 576,700 shares, a decline of 15.3% from the December 15th total of 681,100 shares. Based on an average daily volume of 232,400 shares, the short-interest ratio is currently 2.5 days. Currently, 4.5% of the company's stock are short sold.
View Neuronetics' Short Interest
.

Who are some of Neuronetics' key competitors?

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

Who are Neuronetics' key executives?

Neuronetics' management team includes the following people:
  • Mr. Stephen J. Furlong M.S., VP, CFO & Member of Office of the Pres (Age 56, Pay $536.71k)
  • Mr. Gregory Harper, VP of Product Devel. & Operations (Age 59, Pay $435.11k)
  • Mr. Keith J. Sullivan, Pres, CEO & Director (Age 62)
  • Mr. W. Andrew Macan, Sr. VP, Gen. Counsel, Chief Compliance Officer, Sec. & Member of Office of the Pres (Age 47)
  • Ms. Janie Bates, VP of Marketing
  • Ms. Sara Grubbs, VP of Sales
  • Ms. Kara Thornton, Sr. Director & Head of HR
  • Mr. Daniel Guthrie, Chief Commercial Officer (Age 43)

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

How do I buy shares of Neuronetics?

Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $14.05.

How big of a company is Neuronetics?

Neuronetics has a market capitalization of $266.60 million and generates $62.66 million in revenue each year. The company earns $-29,040,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Neuronetics employs 122 workers across the globe.

What is Neuronetics' official website?

The official website for Neuronetics is www.neurostar.com.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at (610) 640-4202 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.